This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Joint (JYNT) Reaches 900th Clinic Mark With New Texas Unit
by Zacks Equity Research
The Joint (JYNT) moves from the 800th to the 900th clinic milestone in less than a year.
Humana (HUM) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 0.68% and 0.34%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Molina (MOH) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of 11.88% and 0.52%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Hold Strategy is Apt for The Joint (JYNT) Stock Now
by Zacks Equity Research
The Joint (JYNT) is expected to keep growing due to rising patient visits and new clinic openings.
The Joint (JYNT) Buys Wisconsin Regional Developer Zone Rights
by Zacks Equity Research
The Joint (JYNT) expects the Wisconsin region to hold a total of 53 clinics, of which 21 are currently operating.
The Joint Corp. (JYNT) Surges 10.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
The Joint Corp. (JYNT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
The Joint Corp. (JYNT) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
The Joint Corp. (JYNT) delivered earnings and revenue surprises of 850% and 3.60%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Humana (HUM) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 1.41% and 1.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
The Joint (JYNT) to Enter Puerto Rico With New Franchise Deal
by Zacks Equity Research
The Puerto Rico deal with the Comerfords marks The Joint's (JYNT) first franchise deal outside the continental United States.
The Joint Corp. (JYNT) Misses Q4 Earnings Estimates
by Zacks Equity Research
The Joint Corp. (JYNT) delivered earnings and revenue surprises of -42.86% and 1.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Molina (MOH) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of 0.99% and 4.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Centene (CNC) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Centene (CNC) delivered earnings and revenue surprises of -1.15% and 0.08%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
The Joint (JYNT) 2022 Visits Grow to 12.2M, Adds New Clinics
by Zacks Equity Research
The Joint's (JYNT) clinic network grows 19% year over year in 2022.
The Joint (JYNT) Expands Operations to Alaska With 3 Clinics
by Zacks Equity Research
The Joint's (JYNT) expansionary move is expected to be a prudent one, given the growing demand for affordable and convenient chiropractic care in the region.
Do Options Traders Know Something About The Joint (JYNT) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to The Joint (JYNT) stock based on the movements in the options market lately.
Humana (HUM) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 13.04% and 1.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Humana (HUM): Can Its 3.2% Jump Turn into More Strength?
by Zacks Equity Research
Humana (HUM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
The Joint (JYNT) Acquires 4 Franchised Facilities, Down 5%
by Zacks Equity Research
The Joint (JYNT) anticipates the new acquisition value in Scottsdale to match the price of its previous purchases.
The Joint Corp. (JYNT) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
The Joint Corp. (JYNT) delivered earnings and revenue surprises of -125% and 1.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Humana (HUM) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 17.72% and 1.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Centene (CNC) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Centene (CNC) delivered earnings and revenue surprises of 8.93% and 7.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
UnitedHealth Group (UNH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
UnitedHealth (UNH) delivered earnings and revenue surprises of 1.67% and 1.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
The Joint (JYNT) Buys Northern California Regional Developer Zone
by Zacks Equity Research
The Joint (JYNT) expects the Northern California region to hold 75 clinics, including its right to oversee 56 franchisee clinics.
Molina (MOH) to Join S&P 500 Driven by Medicare Performance
by Zacks Equity Research
Molina Healthcare (MOH) is likely to leave S&P MidCap 400 and replace IHS Markit Ltd. in the S&P 500 Index.
The Joint Corp. (JYNT) Q4 Earnings Lag Estimates
by Zacks Equity Research
The Joint Corp. (JYNT) delivered earnings and revenue surprises of -87.50% and 1.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?